New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
January 26, 2013
16:11 EDTCOV, ACT, ENDP, ABT, TEVAFDA panel recommends new restrictions on painkiller, WSJ says
After two days of testimony, an FDA drug safety advisory panel voted 19-10 to recommended new restrictions on products containing hydrocodone—a category that includes Vicodin--should be reclassified as Schedule II controlled substances, along with other narcotic painkillers such as oxycodone, says the Wall Steet Journal. Hydrocodone products are currently in Schedule III. Reference Link
News For ACT;TEVA;ENDP;COV;ABT From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
<< 1 | 2 | 3 | 4 | all recent news | >>
April 28, 2015
14:36 EDTTEVAFDA approves first generic generic versions of Abilify
Subscribe for More Information
10:19 EDTACTPershing Square lists Herbalife, Actavis as top Q1 losers
Subscribe for More Information
08:38 EDTTEVATeva to launch Argatroban Injection in the U.S.
Subscribe for More Information
08:10 EDTENDPEndo appoints Matthew Maletta as Chief Legal Officer
Subscribe for More Information
07:46 EDTTEVAMylan rejection of Teva more than posturing, says Oppenheimer
Subscribe for More Information
07:43 EDTABTMead Johnson pushing for changes to WIC program, WSJ reports
The law authorizing the $6B per year WIC program providing food vouchers to women who are pregnant or have young children is up for renewal this year and formula makers, led by top U.S. maker Mead Johnson (MJN), are pushing for change, said The Wall Street Journal. Growth in the program has made it a money-losing venture for baby formula makers who essentially make no profit off formula sold to states as part of the program and Mead Johnson is pushing for changing eligibility requirements, thereby limiting or even shrinking the pool of recipients, the report noted. Other U.S. infant formula makers include Abbott (ABT) and Nestle (NSRGY). Reference Link
April 27, 2015
15:29 EDTTEVADeal between Mylan, Teva still 'exceedingly likely,' says Cowen
Subscribe for More Information
12:25 EDTTEVAOn The Fly: Top stock stories at midday
Subscribe for More Information
11:21 EDTTEVAMylan not going to sell without a fight, says BMO Capital
Subscribe for More Information
10:41 EDTTEVATeva reiterates commitment to acquisition for Mylan for $82 per share
Teva (TEVA) reiterated its commitment to its proposed combination with Mylan (MYL). As previously announced on April 21, 2015, Teva has proposed to acquire Mylan for $82.00 per share, with the consideration to be comprised of approximately 50% cash and 50% stock. Teva’s proposal for Mylan implies a total equity value of approximately $43B. Teva noted that the board and management team are committed to consummating a transaction as soon as possible. It continues to believe that the Teva proposal is "extremely attractive" for Myland stockholders, that owuld deliver more value than any other alternative. As previously announced, the transaction would not be subject to a financing condition or require a Teva stockholder vote. Teva’s proposal is contingent on Mylan not completing its proposed acquisition of Perrigo or any alternative transactions.
09:48 EDTTEVACNBC discusses Mylan patent challenges on Copaxone
Subscribe for More Information
09:22 EDTTEVAMylan board unanimously rejects expression of interest from Teva
Subscribe for More Information
09:20 EDTTEVAMylan board unanimously rejects expression of interest from Teva
07:15 EDTTEVAMylan Perrigo offer makes Teva acquisition more likely, says Wells Fargo
After Mylan (MYL) announced its formal takeover offer for Perrigo (PRGO), Wells Fargo says that Mylan's lower than expected synergy guidance and the confirmation that Mylan shareholders will be required to approve the deal increase the chances that Teva will wind up buying Mylan. Wells continues to believe that Teva can significantly increase its bid for Mylan and that Mylan may have difficulty rejecting such an offer.
06:34 EDTTEVAOncoGenex subsidiary executes termination agreement with Teva
Subscribe for More Information
06:34 EDTTEVACiti says Teva, Mylan deal 'more likely than not'
Citigroup views a Teva (TEVA), Mylan (MYL) combination as "more likely than not" after Perrigo (PRGO) rejected Mylan's (MYL) second proposal to acquire the company. Citi believes investors are likely under appreciating how quickly a potential deal can be reached. It anticipates that the stichting set up by the Mylan board could trigger the call option to issue preference shares. Teva could appeal to the Dutch Enterprise Chamber, which Citi believes would likely constitute a "relatively speedy process." It has a Buy rating on Teva with a $70 price target.
06:33 EDTTEVAOncoGenex regains rights to custirsen executes termination agreement with Teva
Subscribe for More Information
April 24, 2015
16:31 EDTTEVAStocks finish week higher following strong tech earnings
Subscribe for More Information
12:02 EDTTEVAPerrigo plans to reject Mylan new offer, Bloomberg reports
Subscribe for More Information
09:27 EDTACTActavis' Dalvance shows positive Phase 3 results for skin infections
Actavis announced positive top-line results for study DUR001-303, a phase 3 study comparing a single 1500 mg dose of Dalvance with the same total dose given as two-doses one week apart, for the treatment of acute bacterial skin and skin structure infections caused by susceptible Gram-positive bacteria, including methicillin resistant Staphylococcus aureus. Preliminary top-line data demonstrated the 1500 mg single-dose of Dalvance achieved its primary endpoint of non-inferiority to the two-dose regimen at 48-72 hours after initiation of therapy. Actavis plans to file a supplemental New Drug Application with these data in Q3.
<< 1 | 2 | 3 | 4 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use